Company newsForm 8-K
Linde LIN
Linde issues €650 million of 2029 notes and €650 million of 2033 notes
Net proceeds were approximately €1,295 million, after fees to the managers but before other fees and expenses.
GetSignal
On November 12, 2026, Linde issued €650 million aggregate principal amount of 3.700% notes due 2029 and €650 million aggregate principal amount of 4.000% notes due 2033. The notes were issued under a subscription agreement dated November 10, 2026, with the financial institutions named as bookrunners and other managers.
Linde said the net proceeds will be used for general corporate purposes.
Both series have been admitted to the official list of the Luxembourg Stock Exchange and to trading on its Euro MTF market. The notes are unsecured and were issued under Regulation S of the U.S. Securities Act of 1933, as amended.
The notes were issued under a European debt issuance programme established on May 11, 2020, and last updated on May 4, 2026. The base prospectus dated May 4, 2026 was supplemented on October 30, 2026. The programme authorizes notes outstanding of up to €25 billion, or the equivalent in other currencies.
According to the company, the notes may not be offered or sold within the United States or to U.S. persons, absent registration or an applicable exemption. Linde said the programme is valid for one year from May 4, 2026, and that it must then be updated before any further issuance.
Key facts
- 2029 notes
- €650 million, 3.700% coupon
- 2033 notes
- €650 million, 4.000% coupon
- Issue date
- November 12, 2026
- Net proceeds
- Approximately €1,295 million, after managers' fees and before other fees and expenses
- Use of proceeds
- General corporate purposes
Source: Form 8-K filed November 12, 2026.
Written by GetSignal with AI from the company's SEC filing. How we make news
Not investment advice.
More company news
Linde first, then the newest- Canadian Natural Resources agrees to acquire Advantage Energy
CNQ · Canadian Natural Resources · Company release · Nov 16, 2026
- Rio Tinto, BCL and ABG agree to establish fund for Panguna mine legacy impacts
RIO · Rio Tinto Group · Company release · Nov 16, 2026
- Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026
VKTX · Viking Therapeutics · Company release · Nov 15, 2026
- CVS Health study finds GLP-1 medical savings do not fully offset pharmacy spending at current prices
CVS · CVS Health · Company release · Nov 15, 2026
- Rocket Lab reaches 100 Electron launches
RKLB · Rocket Lab · Company release · Nov 14, 2026
